Switching from a GLP-1 medicine to tirzepatide: what changes and what to expect

You've plateaued on semaglutide or liraglutide — now what?

This is where most switching conversations start. You've been on a GLP-1 for several months, the early weight loss was real, but the scale has barely moved in weeks. Before deciding that your medicine has stopped working, it's worth ruling out the obvious: dose, diet drift, and whether you're still in the active phase of response. A prescriber will want to know your current dose and how long you've been on it.

If you genuinely are on the maximum tolerated dose and progress has stalled, tirzepatide is a clinically reasonable next step to discuss. It's the only licensed dual-agonist available in the UK for weight management, targeting both GIP and GLP-1 receptors. In the SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction over 72 weeks than semaglutide 2.4mg in adults with obesity and no diabetes. That doesn't make it universally better for every person, but it does mean there's direct comparative evidence worth considering with your prescriber.

One misconception worth setting aside gently: switching medicines isn't a reset, and it isn't admitting the first one failed. It's a normal part of a treatment pathway that adjusts to how your body is responding. Our clinical team reviews these situations regularly. If you'd like to explore how tirzepatide fits your picture, you can read about our approach to GLP-1 comparisons on the GLP-1 vs tirzepatide overview page.

What actually changes when you move from a single-agonist to a dual-agonist

Semaglutide and liraglutide are GLP-1 receptor agonists: they mimic a gut hormone that slows gastric emptying, reduces appetite, and influences blood-sugar regulation. Tirzepatide adds a second action — it also activates GIP receptors, which appear to amplify the appetite-suppressing and metabolic effects. Whether that extra pathway makes a meaningful difference for you is something your biology will answer; the trial data shows it does for many people.

In practice, a prescriber switching you from semaglutide to tirzepatide will almost certainly not start you on a high dose. Tirzepatide's licensed schedule begins at 2.5mg, and that lower starting pen exists specifically to let your system adjust before titration. The gastrointestinal side-effect profile overlaps with semaglutide, nausea, loose stools, and reduced appetite are common in the early weeks, particularly after a dose increase, and generally settle. The NHS medicines information for tirzepatide sets out the full side-effect list, and the Patient Information Leaflet in your pen box covers storage, injection technique and what to do if you miss a dose.

If you're currently on liraglutide (Saxenda), the switch to tirzepatide involves a bigger step up in evidence base, and we've covered the specifics, including what to expect on the journey of switching from liraglutide to tirzepatide, on a dedicated page. If you've been on Saxenda specifically and want to understand how that transition to Mounjaro works in practice, our page on switching from Saxenda to Mounjaro walks through the dose considerations and what to discuss with your prescriber. The question of timing (whether there's a washout period needed) is one your prescriber answers based on your current dose and how recently you last injected.

Comparing the key facts: GLP-1 medicines vs tirzepatide

The table below summarises the licensed UK medicines most relevant to this decision. These figures come from the respective trial programmes and UK regulatory approvals; your individual results will differ.

Ozempic deserves a plain note here: it contains semaglutide and is sometimes discussed in weight-loss contexts, but in the UK it holds a licence for type 2 diabetes only. It is not approved for weight management, and NICE's appraisal of tirzepatide (TA1026) doesn't consider it an alternative in this setting. If you've been reading about Ozempic online and wondering whether it applies to you, it doesn't, at least not for weight loss through a regulated route.

What the switching process looks like at nume

Every switch request goes through a full clinical review. That means your prescriber looks at your weight history, your current dose, how long you've been on it, and whether you've met any monitoring thresholds. We don't approve switches on the basis of a tick-box form; a named clinician reviews your case. You can see more about our clinical oversight on the clinical team page.

Transfer patients are asked to provide documentary evidence of their current treatment, a dispensing label, a previous prescription, or a pharmacy receipt is usually sufficient. For dose increases, we need evidence you've been stable at your current dose. This isn't bureaucracy for its own sake; it reflects the MHRA's guidance that these medicines require proper clinical supervision, and it protects you.

Switching also has a cost dimension worth considering honestly. Tirzepatide's UK list price rose substantially in September 2025 (the 15mg pen's list price moved from around £122 to around £330) and private prices across providers range roughly £149 to £375 per month by dose. Full context is on the Mounjaro cost page. One transparent price at nume covers your consultation, prescription, medicine, and aftercare. Which medicine, and at what dose, is the clinical conversation; the pricing is stated clearly on our treatment page before you commit to anything.

Which GLP-1 medicine suits you (and whether tirzepatide is the right switch at this point) is a clinical decision our prescribers make with you. If you've previously been on orlistat, our page on switching from orlistat to Mounjaro explains what that transition typically involves, and if you're already on Mounjaro and wondering what comes next, we've also outlined the considerations around switching from Mounjaro to retatrutide for those whose progress has plateaued again at that stage.